The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Oncoceutics
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
 
Sylvia Christine Kurz
No Relationships to Disclose
 
Rohinton Tarapore
No Relationships to Disclose
 
Yazmin Odia
No Relationships to Disclose
 
Nicholas A. Butowski
Honoraria - DelMar Pharmaceuticals; Karyopharm Therapeutics; QED Therapeutics; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Bayer; Jazz Pharmaceuticals
Research Funding - Abbvie; Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Medicenna; Merck; Merrimack; Tocagen
 
Carl Johannes Koschmann
No Relationships to Disclose
 
Dolly Aguilera
No Relationships to Disclose
 
Tobey J. MacDonald
No Relationships to Disclose
 
Guangrong Lu
Employment - Oncoceutics
 
Joshua E. Allen
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Wolfgang Oster
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Karyopharm Therapeutics; Tocagen
Research Funding - Novocure (Inst)
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
(OPTIONAL) Uncompensated Relationships - Xcision Medical Systems
 
Andrew S. Chi
Employment - Mirati Therapeutics; Neon Therapeutics
Consulting or Advisory Role - Cota Healthcare
Patents, Royalties, Other Intellectual Property - Fused Bicyclic Heterocycles as Therapeutic Agents (Inventor) Provisional Patent Application No. 62/742,041 filed on October 5, 2018
Travel, Accommodations, Expenses - Abbvie
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)